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Whole-genome sequencing is a potentially powerful tool for the diagnosis of genetic diseases. Here, we used
sequencing-by-ligation to sequence the genome of an 11-month-old breast-fed girl with xanthomas and very
high plasma cholesterol levels (1023 mg/dl). Her parents had normal plasma cholesterol levels and reported
no family history of hypercholesterolemia, suggesting either an autosomal recessive disorder or a de novo
mutation. Known genetic causes of severe hypercholesterolemia were ruled out by sequencing the respon-
sible genes (LDLRAP, LDLR, PCSK9, APOE and APOB), and sitosterolemia was ruled out by documenting a
normal plasma sitosterol:cholesterol ratio. Sequencing revealed 3 797 207 deviations from the reference
sequence, of which 9726 were nonsynonymous single-nucleotide substitutions. A total of 9027 of the nonsy-
nonymous substitutions were present in dbSNP or in 21 additional individuals from whom complete exonic
sequences were available. The 699 novel nonsynonymous substitutions were distributed among 604 genes,
23 of which were single-copy genes that each contained 2 nonsynonymous substitutions consistent with an
autosomal recessive model. One gene, ABCG5, had two nonsense mutations (Q16X and R446X). This ﬁnding
indicated that the infant has sitosterolemia. Thus, whole-genome sequencing led to the diagnosis of a known
disease with an atypical presentation. Diagnosis was conﬁrmed by the ﬁnding of severe sitosterolemia in a
blood sample obtained after the infant had been weaned. These ﬁndings demonstrate that whole-genome (or
exome) sequencing can be a valuable aid to diagnose genetic diseases, even in individual patients.
INTRODUCTION
Identiﬁcation of a causal mutation provides the most deﬁnitive
diagnosis for a genetic disease. For disorders caused by
mutations in a limited number of genes, conventional Sanger
sequencing can efﬁciently identify the culprit mutation. For
many single-gene disorders, diagnosis by conventional rese-
quencing of candidate genes is not feasible because the
responsible gene(s) has not been identiﬁed, or because the
disease is highly genetically heterogenous. The use of mas-
sively parallel DNA sequencing technologies (1) has the
potential to identify the causative mutation by resequencing
the whole genome (or exome) of affected individuals.
Recently, Ng et al.( 2) used exome resequencing to identify
the gene responsible for Miller syndrome, a rare autosomal
recessive disorder of unknown etiology. A single candidate
gene (DHODH) was identiﬁed by sequencing the exomes of
four affected individuals from three independent kindreds.
Large-scale sequencing can also be useful in evaluating
patients with a suspected genetic disease in whom the diagno-
sis is uncertain. Choi et al.( 3) identiﬁed mutations associated
with congenital chloride diarrhea in several patients from con-
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Bartter syndrome, a renal salt-wasting disease.
The utility of whole-genome resequencing for genetic diag-
nosiswas furtherillustrated byLupskietal.(4),whosequenced
the genome of a proband with Charcot–Marie–Tooth disease,
an inherited peripheral neuropathy that can be caused by
mutations in 39 separate loci (5). Although the entire genome
was sequenced, the authors focused on only those genes
known to cause the neuropathic condition. All affected individ-
uals in the family of the proband were found to be compound
heterozygotes for SH3TC2 mutations identiﬁed in the
proband. One of the mutations (R954X) had been found pre-
viously in unrelated patients with the disease (6).
Severe mongenic hypercholesterolemia can be caused by
defects in several different genes (7). Familial hypercholester-
olemia (FH), an autosomal dominant disorder due to mutations
in the gene encoding the low-density lipoprotein receptor
(LDLR), is the most common and severe genetic form of
hypercholesterolemia (8). The LDLR is a cell-surface receptor
that mediates clearance of low-density lipoproteins (LDL)
from the circulation. Defects in other proteins required for
LDL clearance cause phenocopies of FH: missense mutations
in apolipoprotein (apo) B (9), a ligand for the LDLR, or in
PCSK9 (10), a proprotein convertase that promotes degra-
dation of the LDLR, cause autosomal dominant hypercholes-
terolemia. Mutations in ARH (encoded by LDLRAP), an
adaptor protein required for LDLR internalization (11), or
inactivating mutations in APOE (12), another LDLR ligand,
produce recessive forms of hypercholesterolemia. All these
disorders present with severe hypercholesterolemia, xantho-
mas (cholesterol deposits in the skin and tendons) and prema-
ture coronary artery disease (7).
Hypercholesterolemia can also be caused by mutations in
proteinsrequiredfortheeliminationofsterols.Arare,recessive
disorder, sitosterolemia, is caused by mutations in either of two
ATP-binding cassette (ABC) hemitransporters, ABCG5 or
ABCG8, that heterodimerize to form a duplex that promotes
sterol excretion (13). Mutations in either ABCG5 or ABCG8
result in increased fractional absorption and decreased biliary
excretion of neutral sterols (14). Plant sterols (e.g. sitosterol,
campesterol, stigmasterol), in addition to cholesterol, accumu-
late in the blood and body tissues of patients with this disorder.
Normally plant sterols are selectively eliminated from the body
in the intestine by secretion into the gut lumen or in the liver via
secretion into the bile. Cholesterol levels are more variable in
sitosterolemia than in other genetic hyperlipidemias, but can
be extremely elevated in some patients (15). The diagnosis of
this disease rests on documenting elevated plasma levels of
plant sterols, which are normally very low (,1 mg/dl). Patients
with sitosterolemia have levels of plasma sitosterol that are
.50-fold elevated (15).
In the present study, we used whole-genome sequencing to
identify the molecular defect in an infant with severe hyperch-
olesterolemia of unknown etiology.
RESULTS
The proband for this study was a healthy 11-month-old girl
who presented with subcutaneous xanthomas over the Achilles
tendon (Fig. 1A). Her plasma cholesterol level was 1023 mg/dl
with an LDL-C of 837 mg/dl, HDL-C of 54 mg/dl and trigly-
ceride of 120 mg/dl. Thyroid function and liver function tests
were normal as was her urinalysis. A pedigree of the proband’s
family, with plasma lipid and lipoprotein levels determined 1
month after presentation, is shown in Figure 1B. The proband
was born to unrelated Romanian parents after an unremarkable
pregnancy. The plasma lipid levels of both parents were within
the normal range. The child was exclusively breast-fed for the
ﬁrst 6 months of life and then was slowly weaned off breast
milk. At the time of diagnosis, breast milk comprised 80%
of her dietary intake.
Since the inheritance pattern of the hypercholesterolemia
was most consistent with the disorder being recessive, we
ﬁrst ruled out sitosterolemia by measuring plasma levels of
plant sterols using gas chromatography-mass spectroscopy
(GC/MS). Although the absolute level of sitosterol (2.37 mg/
dl) exceeded the normal range (0.2–1.0 mg/dl), it was well
below those seen in sitosterolemic individuals (14–65 mg/
dl) (16). Plant sterol levels are expressed as a fraction of the
plasma cholesterol level since phytosterols are transported as
consituents of cholesteryl-rich lipoproteins. The sitosterol:cho-
lesterol and the campesterol:cholesterol ratios of the proband
were within the normal range and similar to the levels of
both parents. Next, we sequenced the exons of LDLRAP, the
gene defective in autosomal recessive hypercholesterolemia
(11) and identiﬁed no mutations. To rule out incomplete pene-
trance of a dominant form of hypercholesterolemia, we also
sequenced the coding regions of LDLR and PCSK9 (17,18)
and found no mutations (the oligonucleotides used to sequence
the exons in these genes are available in the referenced
papers).
To provide a more comprehensive screen for possible
mutations causing the hypercholesterolemia in the child,
whole-genome sequencing was performed by Complete
Genomics, Inc. (Mountain View, CA, USA), using a
sequencing-by-ligation method as described in detail pre-
viously (19). Sequencing of the proband’s DNA sample
yielded 138 gigabase (Gb) of mappable sequence, for an
average fold coverage of 49× per base. A total of 3 797 207
deviations from the reference sequence were noted
(Fig. 2A), of which 3 295 207 were single-nucleotide substi-
tutions (including 2 245 981 heterozygous and 1 049 225
homozygous) and 502 000 were insertions, deletions or more
complex rearrangements. Since most Mendelian disorders
are caused by rare single-nucleotide substitutions in coding
regions and exon splice junctions, we restricted our initial
search to nonsynonymous variants and splice junction variants
that were not present in the public repository of sequence var-
iants (dbSNP) or in 16 exomes (2,20) and 5 genomes (J.C.C.
and H.H.H., unpublished data) from 21 individuals who did
not have hypercholesterolemia.
Of the 9726 nonsynonymous single-nucleotide variants
identiﬁed in the proband, 8626 were present in dbSNP and a
further 401 were present in at least one of the 21 sequenced
individuals, leaving 699 novel nonsynonymous SNPs that
were predicted to change an amino acid or a consensus
splice site in 604 genes. Under an autosomal recessive
model, mutations would be expected in both parental alleles.
Two or more novel nonsynonymous variants were present in
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multiple copies in the genome. Next, we queried whether
there were any nonsense mutations among the 23 single-copy
genes that were found to contain two or more novel, nonsy-
nonymous variants. A single gene, ABCG5, contained two
different nonsense mutations: Q16X and R446X (Fig. 2B).
Sanger sequencing conﬁrmed both mutations in the proband
and that her mother and father were heterozygotes for the
Q16X and R446X mutations, respectively (data not shown).
Both these mutations are incompatible with the expression
of a functional protein. The ABCG5-R446X mutation was
observed in a 10-year-old girl with sitosterolemia (21),
whereas the Q16X mutation has not been reported previously.
Thus, the patient had two inactivating mutations in ABCG5,
which is consistent with her having sitosterolemia. Elevated
plasma levels of plant sterols are the sine qua non of this dis-
order, and yet the proband had normal phytosterol levels at
presentation (Fig. 1A). Another blood sample was obtained
when the proband was 2 years of age.
Figure 3A shows the plasma cholesterol levels of the
proband measured at various intervals after the initial blood
sample (Sample 1) was obtained. The patient was initially
treated with high-dose statins plus ezetimibe. On this
regimen, her cholesterol fell dramatically, but she developed
hepatitis, so both medications were withdrawn and her choles-
terol level increased to .600 mg/dl. Ezetimibe was reinsti-
tuted and her plasma cholesterol level progressively fell. A
low dose of statin (rosuvastatin, 2.5 mg/day) was then
added. She was slowly weaned off breast milk and stopped
breastfeeding 1 year after the hypercholesterolemia was ﬁrst
detected. The second blood sample (Sample 2) was obtained
4 months after she stopped breastfeeding and assayed for cam-
pesterol and sitosterol levels together with an aliquot of frozen
plasma (maintained at 2808C) from the original sample
(Sample 1) (Fig. 3B). GC/MS revealed that plasma plant
sterol concentrations increased markedly in the 1 year interval
between the two samples. Her plasma sitosterol level was
8.4 mg/dl and campesterol level was 4.05 mg/dl while her
plasma cholesterol level had fallen to 151 mg/dl. Her sitoster-
ol:cholesterol ratio had increased .100-fold from 0.44 to
5.5 mg/mg. In contrast, the proband’s cholesterol level,
which was very high in her ﬁrst sample, was now within the
normal range. These results are consistent with the molecular
diagnosis of sitosterolemia.
DISCUSSION
The major ﬁnding of this study is that whole-genome sequen-
cing identiﬁed the culprit mutations and provided a deﬁnitive
diagnosis of sitosterolemia in a severely hypercholesterolemic
patient who did not have the classical hallmark feature of the
disease. Although the patient’s genome had more than 3.5
million sequence variations, the substantial majority of these
could be excluded from consideration as disease-causing
mutations because they are common among healthy individ-
uals. The autosomal recessive inheritance pattern of hyperch-
olesterolemia in the proband’s family imposed the further
requirement that both alleles contain rare mutation, which
greatly reduces the number of candidate genes. Thus, whole-
genome sequencing will not only be useful in revealing the
etiology of unknown genetic diseases but also to diagnose
patients with atypical presentation of known diseases.
Why did the patient not have sitosterolemia at presentation
(15)? A likely contributing factor is that she was being
breast-fed when the original sample was obtained. Since
plant sterols are derived entirely from the diet (22), the
plasma of the mother has low levels of these sterols. The
only source of phytosterols in the milk is from plasma, so
the child was exposed to much lower levels of plant sterols
while being breastfed than when consuming a diet containing
fruits and vegetables (23).
A more perplexing question is why plasma levels of choles-
terol in the proband were so high while the child was breast-
feeding, at a time when the circulating levels of plant sterols
were not elevated? The accumulation of noncholesterol
Figure 1. Pedigree of an infant with severe hypercholesterolemia who presented with cutaneous xanthomas. (A) Pictures taken at presentation of cutaneous
(planar) xanthomas in the creases of the Achilles region. Note the orange-yellow hue of the xanthomas. (B) The proband was a 1-year-old offspring of an unre-
lated Romanian couple who had no family history of hypercholesterolemia or of premature coronary artery disease. The child was being breast-fed when a
plasma sample was obtained and sent to Dallas, TX, USA. The total cholesterol and triglycerides were measured enzymatically, and the lipoproteins were quan-
titated by beta-quantiﬁcation. Neutral sterols were analyzed using liquid GC/MS, and the plasma sitosterol and campesterol were expressed as a fraction of total
cholesterol (TC).
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rates of cholesterol synthesis seen in patients with sitosterole-
mia. (24–26). Previously, we showed that stigmasterol, a plant
sterol that accumulates in sitosterolemia, inhibits processing of
a transcription factor, sterol regulatory element binding
protein-2, which is required for the upregulation of cholesterol
synthesis in response to reductions in cellular cholesterol
levels (27). Since ABCG5 and ABCG8 have been found in
all animals that synthesize cholesterol, but not in those that
do not, we proposed that the rigorous exclusion of sterols
other than cholesterol may be essential for the maintenance
of normal cholesterol homeostasis (25). Interestingly, the
proband in the present study developed severe hypercholester-
olemia before accumulating very high levels of plant sterols.
This ﬁnding suggests that the severe hypercholesterolemia
observed in sitosterolemic individuals may reﬂect a failure
to excrete cholesterol into bile, rather than disruption of
cholesterol homeostasis by plant sterols.
Fortuitously, the proband was treated with ezetimibe, a
lipid-lowering agent that reduces the absorption of plant
sterol levels as well as cholesterol. Sitosterolemia has been
shown previously to be effectively treated by blocking the
absorption of neutral sterols using ezetimibe (28). When
absorption of dietary sterols is blocked in a mouse model of
sitosterolemia, cholesterol homeostasis is restored coincident
with a reduction in plant sterol levels (24). The plasma choles-
terol level progressively fell into the normal range with ezeti-
mibe treatment, although the plant sterol levels remain
elevated despite the patient consuming a low cholesterol,
low-plant-sterol diet, which is characteristic of this disorder,
even after more prolonged treatment with a sterol absorption
inhibitor (28).
Although a growing number of reports attest the utility of
both whole-genome and whole-exome sequencing for the
identiﬁcation of mutations in patients with heritable diseases,
the choice of which strategy to pursue remains a subject of
debate. Whole-genome sequencing is potentially comprehen-
sive and obviates the potential problems associated with selec-
tion and incomplete capture of exons, but is substantially more
expensive than exome sequencing using current generation
parallel sequencing protocols and instrumentation. Since
most known single-gene disorders are caused by mutations
that alter the protein-coding sequences of genes (29), exome
sequencing should sufﬁce in most instances for the identiﬁ-
cation of mutations underlying these diseases. Nonetheless,
the favorable cost–beneﬁt ratio of exome sequencing is
likely to decrease as sequencing costs continue to decline
and throughput increases.
MATERIALS AND METHODS
Study subjects
The proband for this study was an apparently healthy infant
girl who came to clinical attention at the age of 11 months
when she was found to have subcutaneous xanthomas over
her Achilles tendon. Her parents provided written informed
consent for genetic analyses to determine the basis for her
hypercholesterolemia, and the family was enrolled into the
study.
Whole-genome sequencing
Whole-genome sequencing was performed by Complete
Genomics Inc. using a sequencing-by-ligation method (19).
Brieﬂy, sequencing libraries were generated by fragmenting
genomic DNA followed by recursive cutting with type IIS
restriction enzymes. Directional adaptors were ligated to the
fragments and the resulting circular substrates were replicated
with Phi29 polymerase (RCR) to yield hundreds of copies of
single-stranded DNA. The resulting concatamers were
adsorbed to grid-patterned arrays, and combinatorial
probe-anchor ligation chemistry was used to read 10 bases
adjacent to each of the 8 anchor sites, providing 30–35 base
Figure 2. Overview of the analysis of sequence variations identiﬁed by whole-genome sequencing. (A) The whole genome of the proband was sequenced by
Complete Genomics, Inc., using a sequencing-by-ligation method as described (19). A total of 138 Gb of mappable sequence was obtained, for a mean fold
coverage of 49×.( B) Conﬁrmation of ABCG5 mutations in DNA samples from the mother and father of the proband.
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reads were aligned to the reference genome (NCBI Build
36.1) or recruited by the mapped mate-pair reads for local
de novo assembly as well as for determining genotyping
calls for each reference position for each genome. Data were
provided as lists of sequence variants (SNPs and short
indels) relative to the reference genome.
Sanger sequencing
The exons and ﬂanking intronic sequences of LDLRAP,
LDLR, PCSK9 and APOE were sequenced by BigDye Ter-
minator chemistry on an ABI3730XL automated sequencer
(Applied Biosystems) using the protocol provided by the man-
ufacturer.
Assay of plasma lipids and lipoproteins
Lipids were assayed in whole plasma and in lipoprotein frac-
tions using enzymatic assays.
Assay of plasma sterols
Sterols, including cholesterol, campesterol and sitosterol, were
measured in petroleum ether extracts of plasma as described
previously (30).
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